- Home
- INMD
INMD
InMode Ltd.
as 07-26-2024 4:00pm EST
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as InMode Ltd. INMD prepares to release earnings report on 01 Aug 2024.
| Founded: | 2008 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.4B | IPO Year: | 2019 |
| Target Price: | $28.83 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.11 | EPS Growth: | 4.98 |
| 52 Week Low/High: | $16.44 - $44.78 | Next Earning Date: | 08-01-2024 |
| Revenue: | $466,258,000 | Revenue Growth: | -1.72% |
| Revenue Growth (this year): | -0.6% | Revenue Growth (next year): | 7.83% |
Latest InMode Ltd. News
INMD Breaking Stock News: Dive into INMD Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
Owens & Minor (OMI) Earnings Expected to Grow: Should You Buy?
MT Newswires
a day ago
InMode Urged by Investor DOMA Perpetual Capital Management to Buy Back Shares in Tender
Zacks
a day ago
Analysts Estimate InMode (INMD) to Report a Decline in Earnings: What to Look Out for
PR Newswire
2 days ago
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
MT Newswires
4 days ago
Jefferies Downgrades InMode to Hold From Buy, Adjusts Price Target to $19 From $21
MT Newswires
9 days ago
InMode Says FDA Clears Morpheus8 Technology for Soft Tissue Contraction
PR Newswire
10 days ago
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
MT Newswires
11 days ago
Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating
Compare INMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMD InMode Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.